Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Inotek Pharmaceuticals Corp    ITEK

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

(d) Exhibits

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:26am CEST

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive AgreementItem 1.01

Entry into a Material Definitive Agreement.

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment to Rule 24b-2 of the Exchange Act for any schedule so furnished.

* * *

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September13, 2017 INOTEK PHARMACEUTICALS CORPORATION
By:

/s/ Dale Ritter

Dale Ritter
Vice President – Finance

EXHIBIT INDEX

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment INOTEK PHARMACEUTICALS CORP ExhibitEX-2.1 2 d421363dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION       AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: INOTEK PHARMACEUTICALS CORPORATION,…To view the full exhibit click here
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

The post Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INOTEK PHARMACEUTICALS COR
09/14 INOTEK PHARMACEUTICALS CORP : Today's Research Reports on Stocks to Watch: Inote..
09/14 INOTEK PHARMACEUTICALS CORPORATION ( : ITEK) Files An 8-K Entry into a Material ..
09/13 INOTEK PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Unregi..
09/01 INOTEK PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Financi..
08/10 INOTEK PHARMACEUTICALS : Patent Issued for Anhydrous Polymorphs of Methyl Nitrat..
08/08 INOTEK PHARMACEUTICALS CORPORATION ( : ITEK) Files An 8-K Departure of Directors..
08/08 INOTEK PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Financi..
08/03 INOTEK PHARMACEUTICALS : reports 2Q loss
08/03 INOTEK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
08/03 INOTEK PHARMACEUTICALS CORPORATION ( : ITEK) Files An 8-K Results of Operations ..
More news
News from SeekingAlpha
09/14 Inotek Pharmaceuticals (ITEK) Announces Merger Agreement with Rocket Pharmace..
09/13 PREMARKET LOSERS AS OF 9 : 05 am
09/12 Inotek Pharma to merge with gene therapy developer Rocket Pharmaceuticals
08/23 INOTEK PHARMACEUTICALS : A Graham-Dodd Style Cigar Butt Investment
08/23 On The Value Of Operating Losses Of Inotek Pharmaceuticals
Financials ($)
Sales 2017 -
EBIT 2017 -29,8 M
Net income 2017 -33,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 0
Capitalization 41,9 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 2,00 $
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
David P. Southwell President, Chief Executive Officer & Director
J. Martin Carroll Chairman
Dale Ritter Secretary, Treasurer & Vice President-Finance
Rudolf A. Baumgartner Chief Medical Officer & Executive Vice President
Cadmus Collins Rich VP-Medical Affairs & Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
INOTEK PHARMACEUTICALS CORP42
AMGEN27.65%135 544
CELGENE CORPORATION24.22%112 572
GILEAD SCIENCES15.37%108 744
REGENERON PHARMACEUTICALS18.08%46 367
VERTEX PHARMACEUTICALS106.41%38 136